MWNA
AQST icon

Marshall Wace North America’s Aquestive Therapeutics AQST Stock Holding History

Marshall Wace North America’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-8,100
Closed -$26K – 1275
2019
Q3 		$26K Buy
+8,100
New +$30.3K ﹤0.01% 1216
2019
Q1 		– Sell
-2,181
Closed -$14K – 1543
2018
Q4 		$14K Buy
+2,181
New +$27.5K ﹤0.01% 1408

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
BCL
Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Marshall Wace North America's AQST Position: Q4 2019 in Review

Marshall Wace North America sold out of Aquestive Therapeutics (AQST) in Q4 2019, closing a stake of 8,100 shares — an estimated $26K sold.

Marshall Wace North America first reported a position in AQST in Q4 2018 and held it in 2 quarters. The position peaked at $26K in Q3 2019. 56 funds tracked by Wall St. Rank hold AQST as of Q4 2019.

  • Marshall Wace North America reported no remaining Aquestive Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Marshall Wace North America sold 8,100 Aquestive Therapeutics shares in Q4 2019, an estimated $26K.
  • Marshall Wace North America first reported a position in Aquestive Therapeutics in Q4 2018 and held it in 2 quarters.
  • Marshall Wace North America's Aquestive Therapeutics position peaked at $26K in Q3 2019.
  • 56 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q4 2019.

Based on Marshall Wace North America's 13F filing for Q4 2019, filed 14 Feb 2020.